Skip to content

Application of PET/CT targeted tumor fibroblast molecular probe FAPI-04 in stage IA lung adenocarcinoma

Application of PET/CT targeted tumor fibroblast molecular probe FAPI-04 in stage IA lung adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080737
Enrollment
Unknown
Registered
2024-02-05
Start date
2023-02-22
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

Index test:18F-FAPI-04 PET/CT,18F-FDG PET/CT

Sponsors

Maoming people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Physical examination found pulmonary nodules less than or equal to 3.0cm, no history of other malignant tumors; 2. Diseases over the age of 18 and without any other impact on the standard treatment regimen; 3. Agree to perform 18F-FDG and F18-FAPI-04PET/CT full body scans and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Less than 18 years old; 2. History of other malignant tumors; 3. History of chemotherapy / radiotherapy; 4. Be in pregnancy / lactation.

Design outcomes

Primary

MeasureTime frame
SUVmax(Standard uptake value max);Sensitivity;Specificity;Accuracy;Positive predictive values;Negative predictive values;

Secondary

MeasureTime frame
Tumor stroma ratio (TSR);FAP expression intensity score;

Countries

China

Contacts

Public ContactHanxiang liang

Maoming people's Hospital

16324556@qq.com+86 178 2585 1268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026